<DOC>
	<DOCNO>NCT01238094</DOCNO>
	<brief_summary>The purpose study compare 2nd line XELIRI/FOLFIRI + simvastatin v XELIRI/FOLFIRI + placebo .</brief_summary>
	<brief_title>Trial XELIRI/FOLFIRI + Simvastatin Followed Simvastatin Maintenance Metastatic Colorectal Cancer</brief_title>
	<detailed_description>To compare progression free survival standard second line chemotherapy ( FOLFIRI , XELIRI ) plus simvastatin metastatic colorectal cancer patient . This trial placebo-controlled study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Histologically documented colorectal adenocarcinoma ( previously fail oxaliplatin ) 2 . Age 19 year old 3 . Performance status ( ECOG scale ) : 02 4 . Measurable evaluable disease 5 . Adequate organ function 6 . Life expectancy â‰¥ 3 month 7 . No history statin treatment within last 12 month 8 . Patients sign write informed consent study entry . 1 . Tumor type adenocarcinoma 2 . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin , papillary thyroid carcinoma prior malignancy treat 5 year ago without recurrence ) 3 . Adjuvant neoadjuvant treatment nonmetastatic ( M0 ) disease allow complete least 6 month prior initiation study treatment . 4 . Prior radiotherapy permit administered target lesion select study , unless progression select target lesion within radiation portal document , provide complete least 4 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>simvastatin</keyword>
	<keyword>second-line chemotherapy</keyword>
</DOC>